Multi-cancer blood tests move into NHS primary care trials
New multi-cancer blood tests are set to be offered in about 200 GP surgeries across England, placing a technology that has largely been discussed in research settings directly into everyday primary care. The government-funded trial, led by the University of Birmingham, is designed to find out whether blood-based cancer screening tools can help doctors identify hard-to-diagnose tumours sooner, particularly abdominal cancers that often present with vague symptoms and are found only after spread.
The study will enroll more than 20,000 patients aged 45 and over who come to their GP with symptoms such as pain or persistent bloating. Those are exactly the kinds of complaints that create diagnostic uncertainty in primary care. They are common, often non-specific, and frequently overlap with benign gastrointestinal or gynaecological conditions, which means a cancer signal can be easy to miss without a more precise triage tool.
One sentence captures the clinical challenge: these cancers are often already advanced when they are finally recognised.
Why GP surgeries are being used as the test site
The test strategy is built around a simple premise: a blood sample could offer a quicker route to deciding which patients need urgent investigation. Patients will provide one or two tubes of blood at their GP practice alongside routine tests. Scientists will then look for proteins or fragments of DNA that may signal cancer and, if present, may be able to identify where in the body the tumour is located.
That approach is biologically plausible because many cancers shed detectable material into the bloodstream long before they produce a clear anatomical clue. In theory, a circulating biomarker test could help bridge the gap between symptom and diagnosis, especially when the symptom pattern does not immediately point to one organ system. For clinicians working in primary care, the value lies less in replacing conventional assessment than in sharpening the next decision: which patient can be watched, and which patient should move quickly to imaging or specialist review.
Prof Peter Johnson, NHS England’s national clinical director for cancer, said detecting abdominal cancer early is notoriously difficult because symptoms can easily be mistaken for other less serious conditions. Earlier diagnosis gives patients a much better chance of successful treatment and survival. That clinical logic sits at the centre of the trial design, which is intended to see whether the test is accurate enough for wider NHS use.
The cancers under investigation
The STRIDE-RCT trial is focused on bowel, small bowel, stomach, oesophageal, pancreatic, liver, bile duct and gallbladder, ovarian, endometrial, kidney, bladder and prostate cancer. That is a broad mix, but the list reflects a common problem: many of these cancers can produce early symptoms that are either subtle or shared with much more ordinary illnesses.
The trial’s emphasis on abdominal and pelvic malignancies is deliberate. Pancreatic, liver and ovarian cancers in particular have a reputation for silent progression or delayed recognition, and the same is true for several gastrointestinal and biliary cancers. In routine practice, clinicians are often forced to decide whether fatigue, discomfort, bloating, altered bowel habits or pelvic symptoms warrant urgent escalation. A test that can improve that decision-making process would be clinically valuable if its performance proves reliable.
Around 71,000 people in England are diagnosed each year with pancreatic, stomach, liver, ovarian or bowel cancer, and nearly 35,000 die from these diseases. Those figures explain why a blood test that can separate cancer risk from everyday symptom noise has attracted so much attention.
Accuracy, false reassurance and the limits of a blood draw
A positive result does not automatically mean there is cancer, and a negative result is not a guaranteed all-clear. That is the core limitation of any biomarker-based screening or triage test, and it matters in primary care. A result that is too sensitive can drive large numbers of unnecessary referrals, scans and anxiety. A result that misses disease can create false reassurance, particularly in patients whose symptoms are already difficult to interpret.
The trial will therefore assess whether the tests are accurate enough for broader NHS use rather than assuming benefit from their existence alone. That distinction is important in cancer medicine, where diagnostic speed is only one part of the equation. The test must also prove that it can direct the right patients into the right pathway without overwhelming services or overlooking disease.
A separate NHS trial of a blood test called Galleri recently failed to meet its main goal of reducing diagnoses of late-stage cancers, although researchers are still assessing its potential benefits. The current study enters that context with a more targeted primary-care design, and its practical question is whether a GP-based blood draw can perform better when used to support evaluation of symptomatic patients rather than population screening.
What the trial could change for patients and clinicians
Health secretary Yvette Cooper said she hoped simple blood tests such as these would help identify patients needing urgent investigation much sooner. Michelle Mitchell of Cancer Research UK said GPs have long needed better tools to help them navigate uncertainty by identifying which patients require further testing, and described the England trial as an important step towards addressing that need.
The bedside implication is straightforward. If the test performs well, a patient with persistent abdominal symptoms could move from an uncertain watch-and-wait plan to a faster cancer workup. If it performs poorly, it could add noise to already stretched referral systems and complicate decision-making rather than improving it.
The trial now has to answer a much narrower question than the public excitement around “multi-cancer” testing often suggests: can this blood test reliably help GPs sort cancer from non-cancer in symptomatic adults, and can it do so well enough to justify routine NHS use? The answer will depend not on the promise of the technology, but on how it behaves in real patients, in real surgeries, with symptoms that rarely announce a diagnosis cleanly.